These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2526150)

  • 41. Enrichment of early HSV-induced proteins in phosphonoformate-treated cells.
    Lehtinen MO; Lehtinen TK; Leinikki PO
    Acta Virol; 1984 Jan; 28(1):11-8. PubMed ID: 6143492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.
    Sandstrom EG; Kaplan JC; Byington RE; Hirsch MS
    Lancet; 1985 Jun; 1(8444):1480-2. PubMed ID: 2409414
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Na+ and pH dependent transport of foscarnet via the phosphate carrier system across intestinal brush-border membrane.
    Tsuji A; Tamai I
    Biochem Pharmacol; 1989 Mar; 38(6):1019-22. PubMed ID: 2522781
    [No Abstract]   [Full Text] [Related]  

  • 44. Efficacy and safety of foscarnet for recurrent orolabial herpes: a multicentre randomized double-blind study.
    Lawee D; Rosenthal D; Aoki FY; Portnoy J
    CMAJ; 1988 Feb; 138(4):329-33. PubMed ID: 2962712
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Foscarnet infusion at home.
    Heley A
    Lancet; 1988 Dec; 2(8623):1311. PubMed ID: 2904032
    [No Abstract]   [Full Text] [Related]  

  • 46. Concentration-dependent effects of foscarnet on the cell cycle.
    Stenberg K; Skog S; Tribukait B
    Antimicrob Agents Chemother; 1985 Dec; 28(6):802-6. PubMed ID: 2935075
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Importance of Foscarnet in the treatment of cytomegalovirus pneumopathy in a patient with acquired immunodeficiency syndrome].
    Brochard L; Salmeron S; Herve P; Petitpretz P; Boissonnas A; Simonneau G; Duroux P
    Presse Med; 1986 Nov; 15(40):2022-3. PubMed ID: 3025830
    [No Abstract]   [Full Text] [Related]  

  • 48. Foscarnet infusion at home.
    Wood G; Whitby M; Hogan P; Frazer I
    Lancet; 1989 Jan; 1(8630):156. PubMed ID: 2563066
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment of fulminant hepatitis B and fulminant hepatitis B and D coinfection with foscarnet.
    Hedin G; Weiland O; Ljunggren K; Strömberg A; Nordenfelt E; Hansson BG; Oberg B
    Prog Clin Biol Res; 1987; 234():309-20. PubMed ID: 2957702
    [No Abstract]   [Full Text] [Related]  

  • 50. In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS.
    Beldekas JC; Levy EM; Black P; Von Krogh G; Sandstrom E
    Lancet; 1985 Nov; 2(8464):1128-9. PubMed ID: 2865599
    [No Abstract]   [Full Text] [Related]  

  • 51. Acyclovir-resistant herpes in AIDS treated with foscarnet.
    Youle MM; Hawkins DA; Collins P; Shanson DC; Evans R; Oliver N; Lawrence A
    Lancet; 1988 Aug; 2(8606):341-2. PubMed ID: 2899762
    [No Abstract]   [Full Text] [Related]  

  • 52. Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
    Bergdahl S; Sönnerborg A; Larsson A; Strannegard O
    Lancet; 1988 May; 1(8593):1052. PubMed ID: 2896890
    [No Abstract]   [Full Text] [Related]  

  • 53. Sensitivity of cytomegalovirus to intravenous foscarnet treatment.
    Akesson-Johansson A; Lernestedt JO; Ringdén O; Lönnqvist B; Wahren B
    Bone Marrow Transplant; 1986 Dec; 1(2):215-20. PubMed ID: 2844334
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synergistic inhibition of anatid herpesvirus replication by acyclovir and phosphonocompounds.
    Johnson JC; Attanasio R
    Intervirology; 1987; 28(2):89-99. PubMed ID: 2965115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of phosphonoformate on symptomatic genital herpes simplex virus type 2 infection of guinea pigs.
    Mayo DR; Lucia HL; Hsiung GD
    Intervirology; 1983; 19(1):26-32. PubMed ID: 6298142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
    Jacobson MA; Crowe S; Levy J; Aweeka F; Gambertoglio J; McManus N; Mills J
    J Infect Dis; 1988 Oct; 158(4):862-5. PubMed ID: 2844921
    [No Abstract]   [Full Text] [Related]  

  • 57. Mass spectrometric technique for the determination of N-phosphonoacetyl-L-aspartic acid in serum.
    Roboz J; Suzuki R; Rose E
    J Chromatogr; 1980 Feb; 181(2):195-205. PubMed ID: 7372753
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lipid conjugates of antiretroviral agents. II. Disodium palmityl phosphonoformate: anti-HIV activity, physical properties, and interaction with plasma proteins.
    Camaioni Neto C; Steim JM; Sarin PS; Sun DK; Bhongle NN; Piratla RK; Turcotte JG
    Biochem Biophys Res Commun; 1990 Aug; 171(1):458-64. PubMed ID: 2144114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Herpes simplex type 1 defective interfering particles do not affect the antiviral activity of acyclovir, foscarnet and adenine arabinoside.
    Harmenberg JG; Svensson LT
    Acta Virol; 1988 Mar; 32(2):153-5. PubMed ID: 2899962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reversed-phase ion-pair high-performance liquid chromatographic determination of triclabendazole metabolites in serum and urine.
    Negro A; Alvarez-Bujidos ML; Ortiz AI; Cubría JC; Méndez R; Ordóñez D
    J Chromatogr; 1992 Apr; 576(1):135-41. PubMed ID: 1500447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.